Small cell carcinoma of the bladder and other high-grade neuroendocrine tumors of the urinary tract are rare but aggressive cancers: the average survival is about one year. A trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is studying Lurbinectedin and with or without immunotherapy for these diseases.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Medical Oncology Referral Office at (888) 624-1937 or ncimo_referrals@nih.gov.
Clinicaltrials.gov identifier: NCT06228066
NCI Protocol ID: IRB001523
Official Title: A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.